MedPath

Behaviour of salivary cortisol in kidney failure patients.

Not Applicable
Conditions
Health Condition 1: N189- Chronic kidney disease, unspecified
Registration Number
CTRI/2019/09/021393
Lead Sponsor
Department of endocrinology KEM hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients with clinically stable CKD will be divided on the basis of glomerular filtration rate (GFR) into the following arbitrary four groups: mild (GFR: 60-89 ml/min/1.73 m2), moderate (GFR: 30-59 ml/min/1.73 m2) and severe kidney insufficiency (GFR: 15-29 ml/min/1.73 m2), and patients on haemodialysis. 30 patients from each group, and in addition 30 healthy controls with normal GFR >90 ml/min/1.73 m2) will be recruited.

Exclusion Criteria

1. Patients on exogenous steroid therapy.

2. Subjects on drugs known to alter

Dexamethasone metabolism or CBG (cortisol

Binding Globulin) status.

3. Patients having gingivitis or oral ulcers.

4. Oral tobacco use

Exclusion Criteria for Healthy Volunteers:

1. Pregnancy

2. Subjects on drugs known to alter

Dexamethasone metabolism or CBG (cortisol

Binding Globulin) status.

3. Subjects having gingivitis or oral ulcers.

4. Oral tobacco use

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To derive normative range of salivary cortisol (8 am and 11 pm) in patients with CKD <br/ ><br>Performance of overnight dexamethasone suppressed (ODS) cortisol in patients with CKD <br/ ><br>Timepoint: 12 months
Secondary Outcome Measures
NameTimeMethod
oneTimepoint: None
© Copyright 2025. All Rights Reserved by MedPath